ArticleJournal of clinical neurology (Seoul, Korea)2025
Tenecteplase in Acute Ischemic Stroke: A Scientific Statement From the Korean Stroke Society.
Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Effectiveness of Intravenous Tenecteplase versus Alteplase in Posterior Circulation Ischemic Stroke: A Systematic Review and Meta-Analysis.Brain and behavior · 2026Pooled it
- Tenecteplase in the Extended 4.5-24-Hour Window for Acute Ischemic Stroke: An Updated Meta-Analysis of RCTs with EVT-Stratified Subgroup Analysis.Healthcare (Basel, Switzerland) · 2026Review
- The Importance of Cost-Effectiveness in New Drug Approval: Stroke Burden and Tenecteplase Efficacy.Journal of clinical neurology (Seoul, Korea) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTenecteplase (TNK) is a promising alternative thrombolytic agent for the treatment of acute ischemic stroke (AIS). However, its potential use is being impeded by the lack of regulatory approval and reimbursement policies for TNK in AIS in many countries, including South Korea. To address this therapeutic gap, the Korean Stroke Society developed scientific statement intended to inform policy changes and support the introduction of TNK in regions where it is not yet accessible, with the aim of enabling AIS patients to benefit from this advancement in thrombolytic therapy.
methodsWe reviewed randomized controlled trials (RCTs), meta-analyses, and systematic reviews published between January 2010 and November 2024 involving AIS patients treated with intravenous TNK. Meta-analyses were included if they exclusively evaluated RCTs and provided clinical evidence on the efficacy and safety of TNK. The statements were thoroughly reviewed and finalized by international expert panels after iterative revisions.
resultsThe statements suggest that TNK at 0.25 mg/kg can be considered as an alternative to alteplase for intravenous thrombolysis within 4.5 hours of the onset of AIS. The clinical outcomes in patients with large-vessel occlusion who are candidates for endovascular thrombectomy are better for TNK at 0.25 mg/kg than for alteplase.
conclusionsThese statements are intended to support the adoption of TNK in countries where it is not yet available, including South Korea, by providing up-to-date clinical evidence. Their implementation may broaden the therapeutic options for AIS patients and help align acute stroke care practices with international standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.